Targeting HSP90 for Cancer Therapy: Current Progress and Emerging Prospects

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Heat shock protein 90 (HSP90) is crucial for cancer cell survival and proliferation.
• HSP90 regulates numerous proteins and signaling pathways implicated in oncogenesis.
• Traditional HSP90 inhibitors show preclinical promise but face clinical efficacy and toxicity challenges.

Purpose of the Study:

• To review the structure, function, and role of HSP90 in cancer.
• To analyze the clinical progress of existing HSP90 inhibitors.
• To highlight novel strategies for developing next-generation HSP90 inhibitors.

Main Methods:

• Literature review and analysis of preclinical and clinical data.
• Examination of medicinal chemistry approaches for novel inhibitor design.
• Discussion of emerging strategies including selective, dual, and protein-protein interaction inhibitors, and proteolysis-targeting chimeras.

Main Results:

• Over 20 HSP90 inhibitors have entered clinical trials, demonstrating antitumor potential.
• Existing inhibitors face limitations in clinical efficacy and dose-limiting toxicities.
• Novel strategies aim to improve selectivity and reduce off-target effects.

Conclusions:

• HSP90 remains a validated and promising therapeutic target in oncology.
• Advanced inhibitor designs are crucial for overcoming clinical challenges.
• Future research focuses on developing more effective and safer HSP90-targeted cancer therapies.